Abstract
An accelerator-based boron neutron capture therapy (BNCT) system employing a solid-state Li target can achieve sufficient neutron flux for treatment although the neutron flux is reduced over the lifetime of its target. In this study, the reduction was examined in the five targets, and a model was then established to represent the neutron flux. In each target, a reduction in neutron flux was observed based on the integrated proton charge on the target, and its reduction reached 28% after the integrated proton charge of 2.52 × 106 mC was delivered to the target in the system. The calculated neutron flux acquired by the model was compared to the measured neutron flux based on an integrated proton charge, and the mean discrepancies were less than 0.1% in all the targets investigated. These discrepancies were comparable among the five targets examined. Thus, the reduction of the neutron flux can be represented by the model. Additionally, by adequately revising the model, it may be applicable to other BNCT systems employing a Li target, thus furthering research in this direction. Therefore, the established model will play an important role in the accelerator-based BNCT system with a solid-state Li target in controlling neutron delivery and understanding the neutron output characteristics.
Highlights
An accelerator-based boron neutron capture therapy (BNCT) system employing a solid-state Li target can achieve sufficient neutron flux for treatment the neutron flux is reduced over the lifetime of its target
Establishing a model for the neutron flux using the relationship between the number of gener‐ ated neutrons and the total number of protons delivered to the target sample
This study investigated that the model based on the measurements of the saturated radioactivity can appropriately represent the neutron flux for each of the total number of protons delivered to the target sample (Fig. 7)
Summary
An accelerator-based boron neutron capture therapy (BNCT) system employing a solid-state Li target can achieve sufficient neutron flux for treatment the neutron flux is reduced over the lifetime of its target. BNCT is expected to effectively kill cells that are resistant to conventional radiotherapies when the boron compounds have sufficiently accumulated in the cells[13,15] Using these properties, several clinical studies have been conducted in nuclear reactors, such as Kyoto U niversity[1,2,3,4,18,19], and remarkable clinical outcome of BNCT has been demonstrated in those studies[1,2,3,4,5,6,7,8,9,10]. The article is summed up in the conclusions section with significant outcomes and future scope/limitations
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
